Collectively, these results suggest that BTKi effectively ameliorates MCT-induced PAH and pulmonary vascular remodeling by inhibiting macrophage-related inflammation, which eventually improves functional outcome in PAH. This evidence concerns the gene IBTK and pulmonary arterial hypertension.